Lupin Limited (NSE: LUPIN)
India
· Delayed Price · Currency is INR 2,139.15
+34.90 (1.66%)
Jan 22, 2025, 3:30 PM IST
Lupin Revenue
Lupin had revenue of 56.73B INR in the quarter ending September 30, 2024, with 12.59% growth. This brings the company's revenue in the last twelve months to 214.31B, up 15.19% year-over-year. In the fiscal year ending March 31, 2024, Lupin had annual revenue of 200.11B with 20.25% growth.
Revenue (ttm)
214.31B
Revenue Growth
+15.19%
P/S Ratio
n/a
Revenue / Employee
11.16M
Employees
19,210
Market Cap
959.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | 153.75B | 7.10B | 4.84% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 503.08B |
| Divi's Laboratories | 86.14B |
| Cipla | 262.64B |
| Mankind Pharma | 110.18B |
| Zydus Lifesciences | 214.84B |
| Apollo Hospitals Enterprise | 204.69B |
| Aurobindo Pharma | 302.95B |
| Alkem Laboratories | 128.32B |
Lupin News
- 12 days ago - Lupin completes acquisition of 42.61% stake in Sunsure Solarpark - Business Upturn
- 22 days ago - Lupin acquires Huminsulin from Eli Lilly to strengthen its diabetes portfolio - Business Upturn
- 7 weeks ago - Lupin confirms tentative US FDA approval for Type-2 Diabetes drug Janumet generic - Business Upturn
- 7 weeks ago - Lupin and NAPCON hold walkathon for lung health - The Times of India
- 2 months ago - Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally - Business Upturn
- 3 months ago - Lupin launches first generic of Pred Forte in United States - Business Upturn
- 4 months ago - Lupin signs non-exclusive patent license agreement with Takeda to commercialize Vonoprazan in India - Business Upturn